Abstract. LAG1 longevity assurance homolog 2 (LASS2) is a candidate biomarker in cancer that is dysregulated in various types of tumor, potentially affecting cell growth, invasion and migration. Although its effects on liver cancer metastasis and invasion have been reported, specific phenotypic studies and potential molecular mechanisms have not been completely elucidated in hepatoblastoma (HB). In the present study, the effect of LASS2 on the proliferation, apoptosis and cell cycle of HepG2 HB cells was assessed, and the underlying mechanisms were investigated. The human LASS2 coding sequence was inserted into an adenovirus vector and transduced into HepG2 cells. It was determined that the overexpression of LASS2 inhibited HepG2 cell viability and proliferation, as determined by cell counting kit-8 and colony formation assays, and induced apoptosis by increasing reactive oxygen species, reducing mitochondrial membrane potential and inducing intracellular Ca2+ overload. In addition, the overexpression of LASS2 induced G0/G1 cell cycle arrest through modulating the expression of cell cycle regulatory proteins, including p27, cyclin D1 and cyclin-dependent kinase 4. Immunofluorescence was used to determine that nuclear factor-κB p-p65 was primarily expressed in the cytoplasm rather than in the nucleus; western blot analysis demonstrated that LASS2 downregulated the expression of NF-κB p-p65 relative to its inactive form in HepG2 cells. These findings suggest that LASS2 inhibits proliferation and induces apoptosis in HepG2 HB cells through the mitochondrial apoptotic, NF-κB and cell cycle signaling pathways.

Introduction

Liver cancer is the second most common cause of cancer-associated fatality worldwide, and is one of the few types of neoplasm with a steadily increasing incidence and mortality (1-3). Liver cancer subtypes include hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, mixed hepatocellular cholangiocarcinoma (HCC-CCA) and rarer types, such as hepatoblastoma (HB) (4). HB is the most common pediatric malignant liver cancer (5). Although the survival rate for HB has increased from ~30 to >80% with the application of surgical resection, chemotherapy and liver transplantation (6), the molecular development of this aggressive embryonal tumor remains largely uncharacterized (7). Further research regarding the underlying molecular mechanisms will aid to improve the diagnosis and treatment of patients with HB.

Human LAG1 longevity assurance homolog 2 (LASS2), also known as ceramide synthase 2 or tumor metastasis suppressor gene 1, is a 45-kDa membrane protein (8). The expression of LAG1 longevity assurance homolog 2 (LASS2) protein is primarily confined to the nuclear and endoplasmic reticular membranes (9). A previous study demonstrated that LASS2 knockdown induced autophagy and the unfolded protein response, through its participation in the regulation of endoplasmic reticulum stress (10). As a recently identified tumor suppressor gene, LASS2 may also serve an important role in inhibiting the invasion and metastasis of various types of tumor (11-16). The silencing of LASS2 enhances...
the growth, invasion and migration of HCC (11,12), bladder cancer (13,14), breast cancer (8,15) and prostate cancer (16) cells by regulating ATPase activity. In addition, the reduced tumor expression of LASS2 protein was identified to be associated with a worse prognosis in patients with meningioma (17); LASS2 tumor expression was also observed to be negatively correlated with tumor size, tumor differentiation and TNM stage in patients with HCC (18). Although its effects on HCC metastasis and invasion have been reported, to the best of our knowledge, the precise role of LASS2 in tumorigenesis and its potential effects on HB cell proliferation, apoptosis and cell cycle in vitro have yet to be investigated. Therefore, the proliferation, apoptosis and cell cycle-associated nuclear factor (NF) -κ B p65/p27/cyclin D1/cyclin-dependent kinase 4 (CDK4) signaling pathway were considered to explore the potential role of LASS2 in the tumorigenesis of human HB.

Materials and methods

Adv-LASS2-green fluorescent protein (GFP) recombinant adenovirus vector construction. To construct the recombinant adenovirus vector Adv-LASS2-GFP, the LASS2-GFP (human LASS2 coding sequence, NM_022075; 627 ng/µl) and the pShuttle-CMV recombinant shuttle vector (BAC Biological Technology Co., Ltd., Beijing, China) were digested with HindIII and NotI (New England Biolabs, Inc., Ipswich, MA, USA). The digested vector and insert segments were ligated with T4 DNA ligase. Transformation, plasmid mini-extraction and sequencing were performed to obtain a verified pShuttle-LASS2-GFP recombinant shuttle plasmid. Following this, the pAdxsi vector (BAC Biological Technology Co., Ltd.) and pShuttle-LASS2-GFP were separately digested with I-CeuI and I-SceI, followed by ligation and transformation, to obtain a pAdxsi-LASS2-GFP viral plasmid. Extraction of the viral plasmids was performed, linearized pAdxsi-LASS2-GFP viral plasmid was transfected into 293 cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and seeded in 6-cm sterile petri dishes at a density of 10² cells/well. At 14 days from the initial appearance of colonies, the cells were washed twice with PBS, fixed with 4% paraformaldehyde for 20 min at room temperature and stained with crystal violet for 20 min at room temperature. Subsequently, the number of colonies (≥50 cells) was determined.

Cell culture and transfection. Human HB HepG2 cells (19) were kindly provided and authenticated using short tandem repeat markers by Stem Cell Bank, Chinese Academy of Sciences (Shanghai, China). It is notable that the HepG2 cells are typically misidentified as a HCC cell line, which is frequently erroneously used in HCC research (20,21).

Cells were cultured in the recommended medium, Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 U/ml streptomycin. Cells were incubated at 37˚C in a humidified atmosphere containing 5% CO₂. Cells in the exponential phase of growth were counted, seeded in 6-well plates and transfected with the recombinant adenoviruses (Adv-LASS2-GFP or Adv-GFP control) at 50-70% confluence following 24-h incubation. All assays were performed in triplicate.

Determination of the subcellular localization of LASS2 by confocal laser scanning microscopy. Adv-GFP or Adv-LASS2-GFP vectors were transfected into HepG2 cells that were subsequently incubated for 48 h. Cells were placed on slides, washed three times with phosphate-buffered saline (PBS) and fixed by incubation in 4% paraformaldehyde for 30 min at room temperature. The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) in the dark for 5 min at room temperature and washed three times. A confocal microscope (LSM710; Carl Zeiss AG, Oberkochen, Germany) was used to analyze the expression of the GFP-LASS2 protein, which was detected with the GFP filter at 525 nm, following excitation at 488 nm. The cell nuclei were identified with laser excitation at 340 nm and emission at 488 nm. Images were acquired at ×200 magnification.

Cell counting kit-8 (CCK-8) cell viability assay. Cell viability and cell number were assessed using a CCK-8 assay (Beyotime Institute of Biotechnology, Shanghai, China). HepG2 cells were seeded into 96-well plates at 10³ cells/well. pAdv-GFP or pAdv-LASS2-GFP vectors were transfected into the cells, which were subsequently incubated for 0, 24, 48, 72 or 96 h. The cells were incubated with 10 µl CCK-8 solution for 1 h. The optical density (OD) was measured at 450 nm. The cell proliferation rate (%) = (OD value of the test well - OD value of the background control well) / (OD value of the control well - OD value of the background control) x 100%.

Colony formation assay. The transfected cells were collected and seeded in 6-cm sterile petri dishes at a density of 10³ cells/well. At 14 days from the initial appearance of colonies, the cells were washed twice with PBS, fixed with 4% paraformaldehyde for 20 min at room temperature and stained with crystal violet for 20 min at room temperature. Subsequently, the number of colonies (≥50 cells) was determined.

Cell cycle analysis. HepG2 cells were transfected with Adv-GFP or Adv-LASS2-GFP for 48 h. Subsequently, the cells were harvested, washed with PBS and prepared into single-cell suspension (10⁶ cells/ml, 1 ml/group). The precipitate was removed by centrifugation at 800 x g for 5 min at room temperature and the cells fixed in 500 µ1 70% ice-cold ethanol for 2 h, or overnight. Following this, cells were incubated with 100 µl RNAase at 37˚C for 30 min and stained with 400 µl propidium iodide (Nanjing KeyGen Biotech, Nanjing, China) for 30 min at 4˚C while protected from light. The stained cells were subjected to flow cytometry using a flow cytometer (FACSCalibur; BD Biosciences, San Jose, CA, USA) and the proportion of cells phases in G0/G1, S and G2/M were analyzed using FlowJo software (version 10.6.1; BD Biosciences, San Jose, CA, USA). The proportion of cells phases in G0/G1, S and G2/M were analyzed using ModFit software (version 3.3; Verity Software House, Inc., Topsham, ME, USA).

Annexin V-allophycocyanin (APC)/7-amino-actinomycin D (7-AAD) double staining apoptosis assay. Transfected HepG2 cells were harvested with 0.25% trypsin without EDTA, washed twice with cold PBS and resuspended in 500 µl binding buffer. Following this, 5 µl Annexin V-APC and 5 µl 7-AAD (Nanjing KeyGen Biotech) were added in sequence according to the manufacturer's protocol. Cells were incubated
Subsequently, cells were incubated in 3% H₂O₂ in methanol for 5% CO₂ for 20 min. Cells were collected by centrifugation 48 h. Cells were collected, washed with PBS, resuspended Adv-GFP or Adv-LASS2-GFP vectors were incubated for KeyGen Biotech). Briefly, HepG2 cells transfected with the measured using the JC-1 apoptosis detection kit (Nanjing TUNEL) assay. Apoptosis-associated nuclear DNA fragmentation was detected using a commercial biotin dUTP-labeling TUNEL kit (cat. no. KGA702; KeyGen Biotech) according to the manufacturer's instructions. Briefly, HepG2 cells were seeded onto slides in 6-well plates. Following 48 h of incubation, the slides were dried and washed with PBS three times. Cells were fixed with 4% paraformaldehyde for 30 min at room temperature and permeabilized with 1% Triton X-100. Subsequently, cells were incubated in 3% H₂O₂ in methanol for 10 min at room temperature to block endogenous peroxidase activity, washed in PBS and incubated with a mixture of TdT and fluorescein isothiocyanate dUTP solutions in a humidified chamber at 37°C for 60 min. This was followed by washing in PBS and incubated with streptavidin-conjugated horseradish peroxidase (dilution, 1:100; from the TUNEL kit) in a humidified chamber at 37°C for 30 min. When cells were washed with PBS, DAPI solution was applied, followed by counterstaining with hematoxylin. The dehydrated sections were cleared in xylene, mounted with neutral balsam and enclosed with coverslips. Over 200 cells with brown granules in the nuclei were considered to be TUNEL-positive. Cells were assessed in at least three high-powered fields of view (magnification, x200) under an optical microscope (Olympus Corporation, Tokyo, Japan) to determine the mean percentage of positive cells.

Intracellular reactive oxygen species (ROS) measurement. Intracellular ROS were monitored using dihydroethidium (DHE; Nanjing KeyGen Biotech) as the probe. HepG2 cells were trypsinized, washed with PBS and resuspended in 1 ml serum-free medium supplemented with 10 µM DHE at density of 1x10⁶/ml following transfection. Cells were incubated at 37°C for 20 min in the dark and inverted every 3-5 min to maximize the contact between the probe and cells. Following this, the cells were washed three times with serum-free medium to remove excess DHE. Cellular ROS were subsequently measured using flow cytometry, and fluorescence was read using a fluorescence spectrometer with a 488 nm excitation and 605 nm emission wavelength.

Mitochondrial membrane potential (ΔΨm) assays. ΔΨm was measured using the JC-1 apoptosis detection kit (Nanjing KeyGen Biotech). Briefly, HepG2 cells transfected with the Adv-GFP or Adv-LASS2-GFP vectors were incubated for 48 h. Cells were collected, washed with PBS, resuspended in 500 µl JC-1 working solution and incubated at 37°C with 5% CO₂ for 20 min. Cells were collected by centrifugation (800 x g for 5 min at room temperature), washed twice with 1X incubation buffer and resuspended in 500 µl 1X incubation buffer. The concentration of retained JC-1 dye was determined by flow cytometry with an excitation wavelength of 488 nm and an emission wavelength of 530 nm.

Ca²⁺-ATPase assays. ATPases decompose ATP to produce ADP and inorganic phosphate (22). Therefore, Ca²⁺-ATPase activity was determined using a colorimetric method to detect the inorganic phosphate content. Transfected cells were digested and centrifuged as described above. A total of 500 µl cell suspension was added to each tube to a density of 10⁶ cells/ml. The cells were disrupted by ultrasonic homogenization. The detection of inorganic phosphate was performed with the Ultra Trace Ca²⁺-ATPase assay kit (Nanjing KeyGen Biotech) according to the manufacturer's instructions.

Intracellular Ca²⁺ concentration [Ca²⁺], determination. Transfected cells were washed twice with PBS and a single-cell suspension was prepared by centrifugation of 10⁶ cells/ml at 800 g for 5 min. Calbryte 630 AM (AAI BioQuost, Inc., Sunnyvale, CA, USA) was dissolved in dimethyl sulfoxide to prepare a 2 mM stock solution; a working solution of 20 µM Calbryte 630 AM in Hank's balanced salt solution was also prepared. A total of 500 µl Calbryte 630 AM working solution was added into each well, and the dye-loaded plate was incubated for 60 min, followed by incubation at room temperature in the dark for a further 15 min. Cells were collected by centrifugation at 800 x g for 5 min at room temperature, and washed twice with 1X Hank's buffer with HEPES (HHBS) to remove excess dye. Cells were resuspended in 500 µl 1X HHBS and analyzed using flow cytometry for Calbryte 630 AM content, with an excitation wavelength of 610 nm and an emission wavelength of 640 nm, to determine the [Ca²⁺]i.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was isolated from HepG2 cells using the RNAiso Plus reagent (Takara Bio Inc., Otsu, Japan). cDNA was synthesized using the PrimeScript RT Master Mix kit (Takara Bio Inc.) and the ABI 7500 Real-Time PCR instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The thermocycling conditions used with the ABI7500 detection system were as follows: 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 34 sec. Relative quantification was performed using the comparative Ct (2^ΔΔCt) method (23). All data were normalized to the internal control, GAPDH. The specific primers for human LASS2 and GAPDH used in the present study were as follows: GAPDH, sense 5’-GGAGCGAGATCCCCTCAAAAT-3’ and antisense 5’-GGCTGTGTGTCATCTCATTG3’ (197 bp product); and LASS2, sense 5’-ATCGTCTTCCGCCATGT-3’ and antisense 5’-CGTACTGTCGTTCACTCATCT-3’ (233 bp product).

Immunofluorescence. Cells were cultured on glass coverslips and transfected for 48 h, washed with PBS for 5 min, fixed with 4% pre-cooled paraformaldehyde for 20 min, washed in PBS three times for 5 min each time and incubated with PBS containing 0.1% Triton X-100 (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) on ice for 10 min. Two drops of 3% H₂O₂-methanol solution were added onto each coverslip for 10 min at room temperature to inactivate endogenous peroxidase, followed by washing three times with PBS again. Cells were blocked with ready-to-use normal goat serum kit (cat. no. AR0009; Boster Biological Technology, Pleasanton, CA, USA) for 20 min at 37°C and incubated with 50 µl rabbit anti-human NF-κB p-p65 (Ser536; dilution, 1:100; ONCOLOGY REPORTS 41: 3005-3014, 2019 3007
Western blot analysis. The total protein was extracted from HepG2 cells using a protein extraction kit (Nanjing KeyGen Biotech); protein concentrations were measured using a bicinchoninic acid assay kit (Nanjing KeyGen Biotech) according to the manufacturer’s protocols. An equal amount of protein (10 µg per lane) for each group was separated using SDS-PAGE (10% gels) and electrotransferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked in 5% skimmed milk for 2 h at room temperature and incubated overnight at 4°C with the primary antibodies, including GAPDH (dilution, 1:1,000; cat. no. ab137675; Abcam), NF-κB p65 (dilution, 1:1,000; cat. no. ab85567; Abcam, Cambridge, UK), cyclin D1 (dilution, 1:5,000; cat. no. EM1101; Hangzhou HuaAn Biotechnology Co., Ltd., Hangzhou, China), anti-LASS2 (dilution, 1:300; cat. no. ab137875; Abcam), CDK4 (dilution, 1:2,000; cat. no. ab137675; Abcam), NF-κB p65 (dilution, 1:1,000; cat. no. 8242), NF-κB p-p65 (Ser536; dilution, 1:1,000; cat. no. 3033) and p27kip1 (dilution, 1:1,000; cat. no. 2552; all from Cell Signaling Technology, Inc.). The membranes were washed and incubated with the secondary antibody (horse-radish peroxidase-conjugated goat anti-rabbit IgG; dilution, 1:4,000; cat. no. 5220-0283; KPL, Milford, MA, USA) at room temperature for 1-2 h. The membranes were washed, developed using enhanced chemiluminescent kit (cat. no. SQ101; Epizyme, Shanghai, China) and analyzed by densitometry relative to the control gene using Gel-Pro analyzer 4.0 (Media Cybernetics, Inc., Rockville, MD, USA).

Statistical analysis. All statistical analyses were performed with SPSS (version 22.0; IBM Corp., Armonk, NY, USA) and GraphPad Prism (version 7.0; GraphPad Software, Inc., La Jolla, CA, USA) software. Data are expressed as the mean ± standard deviation of at least three independent experiments. One-way analysis of variance with a least-significant-difference test were used for group comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results

Overexpression of LASS2 inhibits HepG2 cell proliferation. Adenovirus vectors Adv-GFP (vector control) and Adv-LASS2-GFP were generated and successfully transiently transfected into HepG2 cells. The subcellular localization of the LASS2-GFP fusion protein was identified using confocal laser scanning microscope at 48 h post-transfection. The LASS2-GFP fusion protein was localized to the nuclear membrane and cytosol (Fig. 1A).

Furthermore, using RT-qPCR, it was identified that the Adv-LASS2-GFP-transfected cells exhibited a significantly greater LASS2 mRNA expression level compared with those transfected with Adv-GFP or negative control (NC) cells (51.62-fold difference; Fig. 1B). The LASS2 protein expression levels were also analyzed by western blot analysis. The increased expression of LASS2 protein was evident in the Adv-LASS2-GFP transfected cells when compared with the Adv-GFP or NC cells (10.55-fold; Fig. 1C).

To determine the effect of LASS2 overexpression on cell proliferation, CCK-8 and colony formation assays were performed. Cell proliferation was significantly decreased at 48 h post-transfection with Adv-LASS2-GFP when compared with cells transfected with Adv-GFP (Fig. 1D). The overexpression of LASS2 significantly suppressed HepG2 colony formation (Fig. 1E). These results indicate that LASS2 overexpression inhibited the proliferation of HepG2 HB cells.

Overexpression of LASS2 induces G0/G1 cell cycle arrest via modulating cell cycle regulatory proteins in HepG2 cells. To investigate the role of LASS2 in the regulation of the cell cycle in HepG2 cells, the effect of its overexpression on cell cycle progression was assessed. The cell cycle distribution was analyzed using flow cytometry with propidium iodide. The results indicated in Fig. 2A revealed that the overexpression of LASS2 inhibited the cell cycle progression of HepG2 cells in the G0/G1 phase. In the cells transfected with Adv-LASS2-GFP for 48 h compared with NC or Adv-GFP groups, the percentage of cells in the G0/G1 phase was significantly increased to 65.13±3.07%; the proportion of cells in the S and G2/M phases was reduced, with the cells in S phase significantly decreasing from 46.11±1.77 to 33.54±2.30% and the cells in the G2/M phase decreasing from 11.58±1.39 to 2.00±0.84%.

To explore the potential mechanisms for the G0/G1 cell cycle arrest induced by LASS2 in HepG2 cells, the expression of members of the NF-κB p65/p27kip1/cyclin D1/CDK4 signaling pathway, associated with the cell cycle and proliferation in cancer cells, were examined using western blot analysis and immunofluorescence (Fig. 2B-E).

NF-κB is an inducible transcription factor critical for the expression of a variety of genes that affect inflammation, immunity, apoptosis, cell proliferation (24,25) and the cell cycle (26,27). The present results demonstrated that NF-κB p65 activity was suppressed following Adv-LASS2-GFP transfection (Fig. 2B and C). Immunofluorescence analysis revealed that NF-κB p-p65 was widely expressed in the cytoplasm, with negative staining in the nuclei (Fig. 2B). Western blot analysis indicated that the relative expression of NF-κB p-p65 was significantly decreased compared with NC or Adv-GFP groups (Fig. 2C). Although the relative expression level of inactive NF-κB p65 was also down-regulated, the difference was not statistically significant (Fig. 2C).

CDKs are a family of kinases initially identified for their role in the regulation of the cell cycle (28). CDK4 is a key partner for cyclin D1 in the regulation of cell cycle progression from the G1 phase (28). The western blot analysis results indicated that the relative expression of cyclin D1 and CDK4
were significantly reduced by 40.89±5.91 and 46.95±6.43%, respectively, in the cells transfected with Adv-LASS2-GFP compared with the control group (Fig. 2D). To investigate the mechanism for the effect of LASS2 on cyclin D1 expression, western blot analysis was performed to detect the changes in the expression of the CDK inhibitor p27. p27 is a negative regulator of cell cycle progression from G1 to S phase and is considered the most characteristic of CDK regulators. Furthermore, p27 inhibits cyclin-CDK complexes such as cyclin D1-CDK4 (29,30). The present results revealed a significantly upregulated expression of p27 protein (1.46-fold) in the cells transfected with Adv-LASS2-GFP compared with the NC group (Fig. 2E).

LASS2 induces apoptosis in HepG2 cells by increasing ROS, reducing $\Delta \Psi_m$ and inducing $[Ca^{2+}]_{i}$ overload. To confirm whether LASS2 overexpression induced apoptosis in HepG2 cells, the phosphatidylserine on the surface of apoptotic cells and nuclear DNA fragmentation during apoptosis was detected using Annexin V-APC/7-AAD and TUNEL assays, respectively. The proportion of Annexin V-APC and/or 7AAD-positive cells (Fig. 3A) and TUNEL-positive cells (Fig. 3B) was significantly higher in cells transfected with Adv-LASS2-GFP compared with cells transfected with Adv-GFP or NC cells.

To further investigate the mechanisms of LASS2-induced apoptosis, changes in intracellular ROS, $\Delta \Psi_m$ and $[Ca^{2+}]_{i}$, were considered. The intracellular ROS level was determined by flow cytometry analysis with DHE staining. It was revealed that the overexpression of LASS2 significantly elicited ROS generation at 48 h post-transfection (Fig. 4A). To study whether LASS2 induced $\Delta \Psi_m$ collapse in HepG2 cells, $\Delta \Psi_m$ was measured using flow cytometry analysis with JC-1 dye. The LASS2-overexpressing HepG2 cells demonstrated a clear reduction of $\Delta \Psi_m$ (Fig. 4B). Furthermore, the effect of LASS2 on $[Ca^{2+}]_{i}$ was determined by flow cytometry using Calbryte 630 AM fluorescence intensity. LASS2 overexpression promoted a significant increase of $[Ca^{2+}]_{i}$ in HepG2 cells (Fig. 4C), leading to the disruption of intracellular calcium homeostasis. Ca$^{2+}$-ATPase is the major active calcium transport protein in the maintenance of normal $[Ca^{2+}]_{i}$ in a variety of cell types (31). Ca$^{2+}$-ATPase activity was determined using
a colorimetric method by the inorganic phosphate content. A significantly reduced ATPase activity was detected in cells transfected with Adv-LASS2-GFP HepG2 cells compared with the Adv-GFP or NC cells (Fig. 4D).
Figure 3. Overexpression of LASS2 promotes HepG2 cell apoptosis. (A) Apoptosis was detected using flow cytometry with Annexin V APC/7AAD in transfected HepG2 cells. (B) Apoptotic DNA fragmentation was detected using a biotin labeling dUTP TUNEL assay. Scale bar, 50 µm. TUNEL-positive cells in Adv-LASS2-GFP transfected cells were significantly increased. ***P<0.001 as indicated. APC, allophycocyanin; 7AAD, 7-amino-actinomycin D; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; LASS2, LAG1 longevity assurance homolog 2; GFP, green fluorescent protein; NC, negative control.

Figure 4. LASS2 induces apoptosis by increasing ROS, loss of ∆Ψm and [Ca2+]i overload. (A) Intracellular ROS level was determined using flow cytometry analysis with DHE staining. LASS2 elicited ROS generation at 48 h post-transfection with Adv-LASS2-GFP. (B) LASS2 induced ∆Ψm collapse in HepG2 cells, mitochondrial membrane potential was measured by FCM analysis with JC-1 dye. (C) [Ca2+]i in HepG2 cells was determined using flow cytometry and analyzed by Calbryte 630 AM fluorescence intensity. (D) Ca2+-ATPase activity was determined by the content of inorganic phosphate using colorimetric method. *P<0.05, **P<0.01 and ***P<0.001 as indicated. ∆Ψm, mitochondrial membrane potential; ROS, Reactive oxygen species; LASS2, LAG1 longevity assurance homolog 2; GFP, green fluorescent protein; NC, negative control; [Ca2+]i, intracellular Ca2+ concentration.
Discussion

The occurrence and development of tumors is a complex process involving the gradual dysregulation of multiple signal networks. The malignant characteristics of tumor cells, such as unlimited proliferation, apoptosis resistance, invasion and migration, are associated with mitochondrial dysfunction (32). Until the present day, the majority of attention has focused on whether LASS2 can inhibit the growth of cells through repressing the activity of V-ATPase in various types of cancer cell, including HCC (11,12), breast cancer (8) and prostate cancer cells (33). Huang et al (13) reported that overexpression of LASS2 induces mitochondrial apoptosis through downregulating mitochondrial membrane potential in BIU87 and J82 bladder cancer cells. A previous report indicated that LASS2 overexpression induced cell cycle arrest at G0/G1 phase and induced apoptosis via a caspase-dependent mitochondrial pathway in HEK293 and 293T cells (34). Whether LASS2 affects HB cell proliferation, apoptosis and cell cycle progression via the mitochondrial and associated NF-κB signaling pathways has not previously been identified. In the present study, the antiproliferative effect of LASS2 overexpression was validated, and it was identified that LASS2 overexpression induced apoptosis and cell cycle arrest in the G0/G1 phase in HepG2 HB cells. Tang et al (12) reported that overexpression of LASS2 could increase intracellular H+ of HCC cells HCCLM3 via V-ATPase and induce cell apoptosis through the cytochrome c mitochondrial pathway.

The mitochondria are an important site for the generation of ROS in eukaryotic cells, and intracellular calcium stores; at the same time, the mitochondria are the primary switch for intrinsic apoptosis (35,36). ROS serve a second messenger at the same time, the mitochondria are the primary switch for apoptosis and cell cycle arrest. The present results demonstrated that LASS2 overexpression increased the ROS concentration, and disrupted mitochondrial function as evidenced by the loss of ΔΨm and the induction of [Ca2+]i overload, which has not been performed before. An increase in the ROS level could damage mitochondrial membranes and result in apoptosis through the oxidation of mitochondrial pores, thereby disrupting the ΔΨm (44,45). Calcium is a major signaling molecule in the regulation of various aspects of cell function, including the regulation of the cell cycle and apoptosis in a wide variety of cell types (46). Intracellular calcium homeostasis can be controlled by Ca2+-ATPase, calcium channels and calcium stores (47). To the best of our knowledge, the present study is the first to identify that LASS2 overexpression can inhibit the activity of Ca2+-ATPase; it was speculated that the inhibition of the calcium pumps promoted [Ca2+] overload, leading to the imbalance of intracellular calcium homeostasis and triggering a chain reaction leading to the initiation of apoptosis. The production of ROS is typically induced by mutation, hypoxia, inhibitors and the production of mitochondrial complexes I-IV (48,49). Mutation, inhibitors and hypoxia induction were not considered in the present study. It was hypothesized that LASS2 may bind to ROS-producing target sites in the mitochondria to generate ROS. Further study is required to confirm this idea.

Numerous studies have indicated that intracellular ROS act as potent stimuli of NF-κB activation in various types of malignant tumor (50-52). However, whether the LASS2-induced ROS increase activates the NF-κB signaling pathway remains unclear. Thus, the association between ROS and the NF-κB p65 signaling pathway was explored. The western blot analysis results indicated that the phosphorylation of NF-κB p65 was significantly reduced subsequent to the upregulation of LASS2. The immunofluorescence staining and confocal microscopy results revealed that LASS2-elicited ROS generation may have impeded the translocation of NF-κB p-p65 to the nucleus. NF-κB is important in cell proliferation, apoptosis and cell cycle regulation to affect normal and malignant cell growth (53,54). The activation of NF-κB affects G0/S and G2/M progression, and the CDK/CDK inhibitor system (55). Thus, the expression of cell cycle regulatory proteins, such as cyclin D1 and CDK4, and the cell cycle inhibitor p27 were examined. The data indicated that the overexpression of LASS2 reduced the relative protein expression of cyclin D1 and CDK4, and upregulated p27 protein expression. Other reports have indicated that NF-κB promotes G1-to-S-phase transition, potentially through cyclin D1 (56,57). NF-κB p65, but not p50, is a downstream mediator of arsenite-induced p27\textsuperscript{10} protein upregulation in IKKβ\textsuperscript{-/-} cells (58), and p27 enhances NF-κB transactivation activity (54). p27 upregulation is particularly associated with G0 quiescence (59) and the inhibition of cyclin D/CDK4 (60). Taken together, this suggests that LASS2 overexpression induced G0/G1 cell cycle arrest via the NF-κB p65/p27/cyclin D1/CDK4 signaling pathway.

In conclusion, the results of the present study provide novel evidence to demonstrate that LASS2 is associated with mitochondrial apoptosis and NF-κB p65/p27/cyclin D1/CDK4 signaling pathway regulation in HepG2 HB cells. These results may form the theoretical basis for understanding HB tumorigenesis and provide a potential therapeutic target for HB, although further study such as knockdown LASS2 in hepatocytes and other hepatoma cells is required to verify and explore more potential mechanisms of the LASS2 gene in vivo and in vitro.

Acknowledgements

Not applicable.

Funding

The present work was supported by grants from National Natural Science Foundation of China (grant no. 81460317), Nation High-tech R&D Program of China (grant no. 2014AA022301), Guizhou Province Medical Science and Technology Project (grant nos. [2016]1174, LKZ [2011]32 and gzwjkj2015-1-015).

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YY, XY, XM designed the study and drafted the manuscript. YY, XY, XO, JX performed the experiments. LL, GY analyzed,
interpreted the data and critically revised the manuscript. YY and TZ performed the statistical analyses. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


